Clinical Trial News and Research

RSS

Telmisartan potent against stroke

Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.

13 Dec 2007

Improving health care for older adults

Most older adults obtain their health care in the offices of busy primary care physicians or, in the case of those without physicians, in even busier hospital emergency departments.

13 Dec 2007

Epigenomic test that could improve treatment for specific gastric cancers

A study by researchers at the John Wayne Cancer Institute at Saint John's Health Center in a recent issue of Journal of Clinical Oncology identifies activation of the enzyme COX-2 in gastric cancer tumors as a prognostic indicator for poor outcome.

12 Dec 2007

FDA and Pharsight continue to collaborate under CRADA

Pharsight Corporation has provided an update on its Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).

12 Dec 2007

Bosutinib safe, effective for chronic myelogenous leukemia

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

12 Dec 2007

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Updated clinical trial results show that the drug dasatinib (Sprycel) continues to be highly effective in patients with chronic myelogenous leukemia who were unable to tolerate Gleevec or who developed resistance to it, reports a team led by researchers at Dana-Farber Cancer Institute.

12 Dec 2007

Cancer cell line developed that is resistant to new cancer therapy

A cancer cell line that is resistant to one of the newest classes of cancer treatments has been developed by researchers who already are using it to determine what else to give patients when this happens.

12 Dec 2007

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review

A leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

12 Dec 2007

Adult stem cell heart attack study updated

Doctors are using patients' own bone marrow stem cells (progenitor cells) to treat the damage to cardiac muscle after a heart attack in a study at Emory University School of Medicine.

12 Dec 2007

Vaccine shows promise in preventing glandular fever

A new study suggests that a vaccine targeting Epstein-Barr virus (EBV) may prevent infectious mononucleosis, commonly known as "mono" or "glandular fever".

10 Dec 2007

Physicians seek strategies to improve the quality of sleep in ICU

The sleep patterns of patients in the intensive care unit are so superficial that they barely spend any time in the restorative stages of sleep that aid in healing, UT Southwestern Medical Center physicians have found.

10 Dec 2007

ImmunoVaccine Technologies to acquire Immunotope

ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.

10 Dec 2007

Mild chemo before stem cell transplant causes long-term remission of follicular lymphoma

Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

10 Dec 2007

Resverlogix receives FDA approval to start clinical trial for RVX-208

Resverlogix Corp. has announced that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL.

10 Dec 2007

FDA approves trial for SKCC breast cancer vaccine

The Federal Drug Administration announced Friday approval of a Phase 1 clinical trial designed to study a breast cancer vaccine developed at the Sidney Kimmel Cancer Center.

10 Dec 2007

Children with sickle cell disease, silent strokes show some relief with blood transfusions

A group of children who have sickle cell disease and who experience silent strokes showed some relief from the silent strokes with blood transfusion therapy, researchers at Washington University School of Medicine in St. Louis have found.

10 Dec 2007

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.

10 Dec 2007

New minimally invasive method to repair tears in the aorta

Tears in the aorta which affect thousands of people each year coast to coast, may soon be treated with a much less invasive technique that could dramatically improve patients' chances of survival.

10 Dec 2007

Vaccine improves event-free survival for leukemia patients

Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

10 Dec 2007

Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids

Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, M.D. at the American Society of Hematology's annual meeting.

10 Dec 2007